Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 9« First...23456...Last »

Novartis Buys U.S. Sickle Cell Drugmaker Selexys

Novartis exercised its option to acquire Selexys Pharmaceuticals based on the SUSTAIN Phase II clinical trial of SelG1, an anti-P-selectin antibody.

Read More »

GlaxoSmithKline seeks U.S. approval for triple lung drug

GlaxoSmithKline filed its new three-in-one inhaled lung drug for U.S. approval, potentially putting it on track to reach the market ahead of rivals in 2017.

Read More »

Novartis backs off from 2016 date for testing Google autofocus lens

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is “progressing steadily.”

Read More »

Artificial pancreas safe for hospitalized diabetics

An automatic insulin delivery system that has performed well in type 1 diabetes patients also proved safe and feasible for type 2 diabetes patients on a general hospital ward, according to a U.K. study.

Read More »

Americans want Trump to focus on healthcare first

Healthcare is the top issue Americans want Donald Trump to address during his first 100 days in the White House, according to a Reuters/Ipsos poll, reflecting apparent frustration over rising costs for prescription drugs and medical coverage.

Read More »

FDA rejects Spectrum’s bladder cancer drug

Spectrum Pharmaceuticals Inc. said the U.S. Food and Drug Administration rejected the drugmaker’s bladder cancer treatment, apaziquone.

Read More »

Sanofi Pasteur Abandons Bladder Cancer Drug

Sanofi Pasteur in an email to urologists informed physicians and patients that it will stop manufacturing TheraCys, BCG Live, for bladder cancer recurrence.

Read More »

Struggling OncoGenex Axes More Jobs to Conserve Cash

Shares of OncoGenex Pharmaceuticals were down about 4 percent after reports surfaced the company was terminating employees to conserve capital as company leaders determine new strategic plans.

Read More »

WHO says funds secured for Africa pilots of world’s first malaria vaccine

Funding for phase one of pilot deployments of the world’s first malaria vaccine in sub-Saharan Africa has been secured and immunization campaigns will begin in 2018, the World Health Organization (WHO) said.

Read More »

McCann Torre Lazur’s #worthliving: The Orange Project Aims to Save Lives

Inspired by the experience of a colleague who lost a loved one to suicide, a team of volunteers at the healthcare communications company McCann Torre Lazur has spent the last two years engaging their creative powers to build a powerful call to action for suicide prevention.

Read More »

No early win for cholesterol drug Praluent

Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.

Read More »

Obama says would support Trump moves to improve U.S. healthcare

President Barack Obama said he would support any move by President-elect Donald Trump to improve healthcare for Amercicans.

Read More »

Conflict of interest for NFL doctors to report to teams: Harvard study

The doctors who patrol the sidelines of NFL games to assess whether injured players can safely return to the field should report to the league and players’ union rather than individual teams, said a Harvard University study.

Read More »

Two Private Investigators Accuse GlaxoSmithKline of Hiring Them Under False Pretenses

Two private investigators have filed a lawsuit against GlaxoSmithKline, claiming the pharma giant hired them to investigate an alleged whistleblower in China under false pretenses – an alleged whistleblower who turned out to be innocent. That investigation lead to their own imprisonment in a Chinese prison.

Read More »

Gilead Myelofibrosis Drug Flops in Phase III

Gilead Sciences announced top-line results from two Phase III clinical trials with mixed results for the Janus kinase (JAK) inhibitor momelotinib.

Read More »

Amgen, Novartis aim for big, crowded migraine market after new drug data

Episodic migraine sufferers reported fewer debilitating headaches per month after using Amgen and Novartis’ investigational drug erenumab, compared to trial participants who got a placebo.

Read More »

Japan sets 50 percent price cut for Bristol-Myers’ Opdivo cancer drug

Japan’s health ministry has set a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol-Myers Squibb Co. and marketed in the country by Ono Pharmaceutical Co. Ltd.

Read More »

New St. Jude heart pumping device proves superior to older model: study

St. Jude Medical Inc.’s new, smaller HeartMate 3 heart pumping assist device proved superior to its older HeartMate II in advanced heart failure patients, according to the first data from a large trial.

Read More »

Ex-sleuths sue GlaxoSmithKline over imprisonment in China

Two former corporate investigators have sued GlaxoSmithKline, alleging the drugmaker misled them and induced them to investigate an innocent person, resulting in their imprisonment.

Read More »

Drug price pressure helped sink Novo’s insulin pill

Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk’s bid to make an oral form of insulin.

Read More »

Page 4 of 9« First...23456...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom